Yaoming Kangde: In the first half of 2022, the net profit of returning mother increased by 73.29% year -on -year

On July 26, 2022, Yaoming Kangde (603259.SH/02359.HK) announced the 2022 semi -annual report.

It was 3.996 billion yuan, an increase of 86.48%year -on -year.

The company's total assets were 61.913 billion yuan, an increase of 12.31%year -on -year.

Specifically, from the perspective of the business income of various business sectors in the company, the chemical business increased by 101.91%year -on -year to 12.974 billion yuan, the test business increased by 23.62%year -on -year to 2.605 billion yuan.The CTDMO business of gene therapy increased by 35.73%year -on -year to 615 million yuan, and the domestic new drug R & D service department decreased by 26.69%year -on -year to 456 million yuan.

During the period, the company's research and development costs were 657 million yuan, an increase of 62.50%year -on -year. During the reporting period, the company continued to increase R & D investment and further strengthen the Protac, oliguucleotide, polypeptide, and antibody coupling drugs (ADC) (ADC), Double -resistant, cells and genes such as new molecular types.

- END -